More Images
The Centers for Disease Control and Prevention (CDC) and US Food and Drug Administration (FDA) recently released studies examining whether there was an association between the use of oral antiviral treatments for COVID-19 and the occurrence of COVID-19 rebound. COVID-19 rebound is typically described as a recurrence of symptoms or a new positive viral test after testing negative.

Researchers found that there was no consistent association between antiviral treatment for COVID-19 (eg, nirmatrelvir-ritonavir) and COVID-19 rebound. Among people at higher risk for progression to severe disease, the substantial benefits of treatment outweigh the risk for COVID-19 rebound.

Current evidence, including randomized controlled trial and observational data, suggests that SARS-CoV-2 rebound occurs initially as a mild illness 3-7 days after resolution of the initial acute illness, occurs in both treated and untreated patients, and is not associated specifically with receiving nirmatrelvir-ritonavir.

There was no increased risk for hospitalization or death among people with rebound. Moreover, rebound occurs when there is variable, host-mounted immune response to infection during the course of illness.
Head over to Medscape to read the full story.